Some thoughts on the reporting of adverse events in phase II cancer clinical trials

被引：8

作者：

Anderson, Stewart J. ^{[1
]}

机构：

[1] Univ Pittsburgh, Grad Sch Publ Hlth, Natl Surg Adjuvant Breast & Bowel Project Biostat, Pittsburgh, PA 15260 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 24期

关键词：

D O I：

10.1200/JCO.2006.06.9856

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3821 / 3822

页数：2

共 7 条

[1] Early detection of toxicity and adjustment of ongoing clinical trials: The history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program [J].

Goldberg, RM ;

Sargent, DJ ;

Morton, RF ;

Mahoney, MR ;

Krook, JE ;

O'Connell, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (23) :4591-4596

[2] Dealing with a deluge of data: An assessment of adverse event data on North Central Cancer Treatment Group trials [J].

Mahoney, MR ;

Sargent, DJ ;

O'Connell, MJ ;

Goldberg, RM ;

Schaefer, P ;

Buckner, JC .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9275-9281

[3]

*NAT CANC I, 2003, CLIN DAT UPD SYST CD

[4]

*NAT CANC I, 1999, COMM TOX CRIT V2 0 C

[5] Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel [J].

Rothenberg, ML ;

Meropol, NJ ;

Poplin, EA ;

Van Cutsem, E ;

Wadler, S .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3801-3807

[6] Adverse event reporting in publications compared with sponsor database for cancer clinical trials [J].

Scharf, Orit ;

Colevas, A. Dimitrios .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3933-3938

[7] The reliability of medical record review for estimating adverse event rates [J].

Thomas, EJ ;

Studdert, DM ;

Brennan, TA .

ANNALS OF INTERNAL MEDICINE, 2002, 136 (11) :812-816

← 1 →